5 Stocks You Should Sell According to Motley Fool

Page 5 of 5

1. Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)

Number of Hedge Fund Holders: 20

Percentage Decrease in Stake in Q4: 11%

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) is headquartered in Novato, California, operating as a biopharmaceutical company that focuses on the commercialization of treatments for rare and ultra-rare genetic diseases in North America, Europe, and internationally.

Securities filings for Q4 2021 reveal that Motley Fool disposed 11% of its Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) stake. The hedge fund held 119,993 shares of the company in the December quarter, worth $10 million, representing 0.64% of the total 13F holdings. 

On March 16, Credit Suisse analyst Tiago Fauth upgraded Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) to Outperform from Neutral with a price target of $105, up from $99. The analyst sees a “compelling risk/reward” profile on the shares ahead of the company’s Angelman syndrome program update. The analyst told investors that they might be ignoring how low the efficacy bar is in this potential multi-billion dollar market.

Among the hedge funds tracked by Insider Monkey, 20 funds were bullish on Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) at the end of the fourth quarter of 2021. Panayotis Takis Sparaggis’ Alkeon Capital Management is the biggest shareholder of the company, with 2.30 million shares valued at $194 million.

You can also take a look at 10 Stocks to Buy in April According to Jim Cramer and 7 Best Stocks to Buy Now According to Bill Ackman

Page 5 of 5